Guideline Covers Trial Considerations for Assessing Biosimilarity in Europe

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency wants biosimilars makers to use pharmacodynamic markers alongside pharmacokinetic data to demonstrate biosimilarity.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor